Bausch Health's Liver Drug Fails, Raising Pipeline and Debt Questions

LAVAL, QC – January 23, 2026 – Bausch Health Companies Inc. delivered a significant blow to patients and investors today, announcing that its highly anticipated Phase 3 clinical program, RED-C, failed to meet its primary goals. The two global trials were evaluating an investigational drug, amorphous-rifaximin solid soluble dispersion (SSD), intended for the primary prevention of hepatic encephalopathy (HE), a severe neurological complication of liver cirrhosis.

The news sent the company's stock (NYSE:BHC, TSX:BHC) tumbling by as much as 10% in trading, reflecting the high stakes associated with the trial. While the company confirmed the drug was safe and well-tolerated, its inability to effectively delay the first episode of HE leaves a critical void in patient care and raises pressing questions about the future of Bausch Health's hepatology pipeline and its ability to manage a mountain of corporate debt.

A Profound Disappointment for Patients

The failure of the RED-C program represents a profound disappointment for the millions of people worldwide living with liver cirrhosis, a condition that the CDC ranks as the ninth leading cause of death in the United States. Hepatic encephalopathy is a debilitating progression of the disease, characterized by a decline in brain function that can lead to confusion, personality changes, and coma. Currently, there is no approved therapy to prevent the first onset of this condition.

"We are disappointed in the results, as there is currently no approved treatment for these patients," said Thomas J. Appio, Chief Executive Officer of Bausch Health, in a statement. The scale of the RED-C program, which enrolled over 1,000 patients across 398 sites in 17 countries, underscores the global recognition of this unmet medical need.

For these patients and their families, the trial's outcome means the wait for a preventative therapy continues. The drug's failure highlights the immense challenges inherent in late-stage pharmaceutical development, particularly for complex diseases where the biological pathways are not fully understood. Appio extended his gratitude to the patients and research teams, acknowledging their crucial role in the pursuit of a treatment that, for now, remains elusive.

Wall Street Reacts Amid Mounting Financial Pressure

The market's reaction was swift and negative, though some analysts suggest the company's chronic challenges had already tempered expectations. Financial firms like Truist maintained a "Hold" rating, pointing to ongoing uncertainties in the company's pipeline. The stock's performance over the past year, which saw a decline of over 15% leading up to the announcement, indicates that investors were already wary of potential setbacks.

However, this specific failure lands at a particularly vulnerable time for Bausch Health. The company is grappling with a staggering debt load of approximately $21 billion, a legacy of its past as Valeant Pharmaceuticals. A significant portion of this debt, roughly one-third, is due by 2027, creating immense pressure to generate cash flow and secure new revenue streams. This financial strain has already stalled the planned separation of its profitable eye-care unit, Bausch + Lomb, as creditors have resisted a move that could weaken the parent company's balance sheet.

The RED-C program was a cornerstone of Bausch Health's strategy to navigate these financial headwinds. A successful outcome would have opened up a substantial new market and provided a much-needed growth driver. Its failure now forces the company to re-evaluate its path forward under intensifying financial scrutiny.

A High-Stakes Gamble on a Proven Molecule

The trial was not for an entirely new chemical entity but for an enhanced formulation of rifaximin, the active ingredient in Bausch Health's blockbuster gastrointestinal drug, Xifaxan. Xifaxan is already approved to reduce the risk of recurrent episodes of HE in patients who have already suffered one, and it is a major revenue generator for the company's Salix segment.

The amorphous-rifaximin SSD formulation was designed to improve upon the original by allowing the drug to dissolve and act throughout the entire gastrointestinal tract, not just the small intestine. The hope was that this enhanced delivery would prove effective in the much larger patient population that has cirrhosis but has not yet experienced an HE episode—a market estimated to be potentially three times the size of the current indication for Xifaxan.

This strategic bet was made even more critical by the looming patent cliff for Xifaxan, with its market exclusivity expected to expire by the end of 2027. The failure of its would-be successor leaves a significant hole in the company's long-term revenue planning and intensifies the search for new blockbuster candidates within its portfolio.

Searching for the Next Chapter

Despite the setback, Bausch Health has publicly reaffirmed its commitment to the field. In his statement, CEO Thomas Appio noted that the company is "currently reviewing the full dataset to determine potential new development opportunities." This analysis could potentially uncover benefits in a specific subgroup of patients or provide valuable insights for future research, though it does little to soften the immediate blow.

Looking ahead, the company is not without other prospects in its hepatology pipeline. A key asset is larsucosterol, an epigenetic modulator in development for the treatment of alcoholic hepatitis. Acquired through the purchase of DURECT Corporation in mid-2025, larsucosterol showed a promising mortality benefit in its Phase IIb trial and is slated to advance to Phase III. This gives the company another shot on goal in a different, albeit related, area of liver disease.

Meanwhile, the broader scientific community continues its quest to prevent HE. Researchers are exploring a range of alternative mechanisms, from ammonia scavengers and advanced probiotics to fecal microbiota transplants, signaling that the drive to solve this medical challenge persists. For Bausch Health, the immediate focus will be on communicating a revised strategy to anxious investors, with all eyes turning to its upcoming fourth-quarter and full-year 2025 financial results call, scheduled for February 18, 2026.